Alnylam announces positive results for RNAi therapy Alnylam Pharmaceuticals today announced positive results from a Phase 2 clinical trial of cemdisiran (ALN-CC5), an investigational targeted complement RNAi therapy jointly developed with Regeneron.

2025/01/0221:29:33 science 1681

Alnylam announces positive results for RNAi therapy

Alnylam announces positive results for RNAi therapy Alnylam Pharmaceuticals today announced positive results from a Phase 2 clinical trial of cemdisiran (ALN-CC5), an investigational targeted complement RNAi therapy jointly developed with Regeneron. - DayDayNews

Alnylam Pharmaceuticals today announced positive results from a Phase 2 clinical trial of cemdisiran (ALN-CC5), an investigational targeted complement RNAi therapy jointly developed with Regeneron. Data analysis shows that this therapy can effectively improve urine protein (proteinuria) values ​​in adult patients with immunoglobulin A nephropathy (IgAN). This data will support the entry of this therapy into Phase 3 clinical trials. ( WuXi AppTec )


For more hot information, insight analysis, research reports, live lectures... Please pay attention to [Hard Technology]
Welcome to search [Hard Technology] on all major platforms and look for accounts with blue logos!
is here to see, understand and connect with hard technology! We focus on optoelectronic chips, artificial intelligence , aerospace, new energy, smart cars, biomedicine , science and technology finance and other industries, and rely on the unique scientific and technological intelligence data owned by the scientific and technological innovation intelligence SaaS service provider Smart Bud. Advantages, work with readers to see technology trends, understand hard technology industries, and connect to the innovative future. "Hard Technology" is produced by the Smart Bud Innovation Research Center.

science Category Latest News